Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      The Genetic Side of Chemotherapy-Related Fatigue

      October 27, 2017
      By Brielle Urciuoli
      Article

      Genes and gender may play a role in who is more likely to experience chemotherapy-related fatigue, according to a recent study.

      While fatigue is one of the most common side effects of chemotherapy treatment, recent research suggests that genetics may play a role, making certain patients with cancer more prone to fatigue than others.

      The study, which was published in the journal Supportive Cancer Care, included 333 adult patients who had breast, gastrointestinal, gynecologic, or lung cancers. All participants received chemotherapy within the past four weeks, and had at least two more chemotherapy treatments scheduled in the future.

      A grading system called the Lee Fatigue Scale was used to rank the patients’ evening fatigue levels. They rated 13 items from zero to 10 each night before bed, comparing their feelings to the previous week. The higher the rating, the more severe their fatigue was.

      In total, 65 patients fell into the “moderate fatigue” group, while 195 fell into the “very high fatigue” group. No patients involved in the study had low levels of fatigue, according to the authors. Those who had very high levels of fatigue were more likely to have alterations in genetic pathways that controlled immune function, inflammation, neurotransmission, energy metabolism, and circadian rhythm.

      There is currently no cure for chemotherapy-related fatigue, and exercise is the only proven intervention that can help decrease fatigue levels in survivors.

      “We were surprised with the identification of two previously undescribed mechanisms underlying fatigue, which include renal function and carbohydrate metabolism,” Elena Flowers, Ph.D., RN, study author and assistant professor at the School of Nursing at University of California San Francisco said in an interview with Oncology Nursing News.

      Further, some patients — particularly those who were women and/or have breast cancer — showed to be more likely to experience high levels of fatigue than others.

      Flowers mentioned that women report higher levels of not only fatigue, but most other cancer symptoms, too. However, why this association occurs is not completely understood. “It may be that women have additional responsibilities (e.g. caring for children) that increase their level of fatigue,” she said. “Additional research is needed to determine the causes for increased fatigue in these women.”

      But regardless of gender or cancer type, the authors emphasized that since 30 percent of survivors experience extreme fatigue, it is vital that researchers develop a better understanding of the symptom and create personalized approaches to ease the burden in survivors.

      “Given the high occurrence rate and significant negative impact of fatigue on patients’ lives, it is imperative that effective treatments be developed for this devastating symptom,” the authors wrote.

      While the findings of this study do not have direct implications for clinical practice at this time, the authors hope that eventually interventions can be created that will target the pathways they found to be associated with higher levels of chemotherapy-related fatigue.

      In addition to studying gene expression, the authors are also examining epigenetic markers, which can point out changes in gene expressions that are not a result of variation in genetic sequences.

      “Epigenetic mechanisms help patients adapt to changes in their environment, including factors like chemotherapy and stress,” Flowers said. “We hope that the integration of gene expression with epigenetics will elucidate a more comprehensive biological model for fatigue.”

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Photo of a woman wearing a blazer and a colorful scarf in front of a blue background
      Photo of a woman with red hair and glasses wearing a black blouse and cross necklace in front of a dark blue background
      Photo of a man wearing a suit with a blue tie in front of a dark blue background
      4 experts in this video
      4 experts in this video
      4 experts in this video
      4 experts in this video
      Photo of a man wearing a suit with a blue tie in front of a dark blue background
      Photo of Hope Rugo, MD
      Image of a woman with blond hair in front of a dark blue background
      Related Content

      graphic of a person with breast tumors

      JSKN003 Shows Activity in Heavily Pretreated HER2+ Breast Cancer

      Chris Ryan
      July 28th 2025
      Article

      Pooled data from early-phase trials suggest JSKN003 is tolerable and active in patients with heavily pretreated HER2-positive disease.


      The Vitals

      Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

      Lindsay Fischer
      November 15th 2023
      Podcast

      Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.


      Graphic of a person with a breast tumor

      Awareness of Actionable Mutations Guides mBC Treatment Post-Endocrine

      Bridget Hoyt
      July 16th 2025
      Article

      Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the care of HR+, HER2- mBC.


      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Lindsay Fischer
      October 2nd 2023
      Podcast

      Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.


      Graphic of a breast with a tumor

      Real-World Data Tie Early Breast Cancer ctDNA to Recurrence, Lower OS

      Jax DiEugenio
      July 14th 2025
      Article

      Data from a research database link ctDNA positivity in early breast cancer with poorer survival and higher recurrence risk.


      Graphic of a breast with a tumor

      Olanzapine/Triplet Cuts Chemotherapy-Induced Nausea, Vomiting in Breast Cancer

      Roman Fabbricatore
      July 11th 2025
      Article

      Those who took olanzapine reported higher levels of satisfaction than patients on placebo.

      Related Content

      graphic of a person with breast tumors

      JSKN003 Shows Activity in Heavily Pretreated HER2+ Breast Cancer

      Chris Ryan
      July 28th 2025
      Article

      Pooled data from early-phase trials suggest JSKN003 is tolerable and active in patients with heavily pretreated HER2-positive disease.


      The Vitals

      Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

      Lindsay Fischer
      November 15th 2023
      Podcast

      Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.


      Graphic of a person with a breast tumor

      Awareness of Actionable Mutations Guides mBC Treatment Post-Endocrine

      Bridget Hoyt
      July 16th 2025
      Article

      Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the care of HR+, HER2- mBC.


      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Lindsay Fischer
      October 2nd 2023
      Podcast

      Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.


      Graphic of a breast with a tumor

      Real-World Data Tie Early Breast Cancer ctDNA to Recurrence, Lower OS

      Jax DiEugenio
      July 14th 2025
      Article

      Data from a research database link ctDNA positivity in early breast cancer with poorer survival and higher recurrence risk.


      Graphic of a breast with a tumor

      Olanzapine/Triplet Cuts Chemotherapy-Induced Nausea, Vomiting in Breast Cancer

      Roman Fabbricatore
      July 11th 2025
      Article

      Those who took olanzapine reported higher levels of satisfaction than patients on placebo.

      Latest Conference Coverage

      Proactive Rash Management Vital for PI3K, AKT Inhibition in Breast Cancer

      Understanding How On-Target and Off-Target ADC Toxicities Work

      Monitoring for Infection-Like AEs Is Essential for CIML NK in GI Cancers

      Belzutifan May Lengthen Quality-Adjusted Survival in Advanced RCC

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.